ONVO Organovo Corp: Price-to-Projected Revenue Ratio

Organovo Holdings, Inc. - graphic logo of issuer ONVO

Organovo Holdings, Inc. (ONVO) is implementing an ethical approach by replacing animal testing with 3D bioprinting of tissues. The forward P/S ratio helps assess the asset's attractiveness, while the value of 28.70 reflects the metric's balance. The company relies on its unique NovoGen technology to create liver structures in high demand among pharma behemoths. The stability of R&D processes is ensured by regular updates to bioprinters to achieve maximum cell positioning precision.

Organovo - ONVO Market Cap to Expected Sales Ratio (period 07/04/2022 - 04/24/2025)

Summary analytical data breakdowns for organovo.com (ONVO)

- market price and analyst price targets:
Initial company analysis:ONVO (Organovo Holdings Inc)
Original product of Organovo Holdings, Inc.

This indicator assesses market capitalization relative to expected sales volume, allowing investors to determine the degree of asset overvaluation based on forward-looking data. By analyzing the forward price-to-sales ratio, one can see how the lack of current revenues at Organovo Holdings, Inc. (ONVO) and the R&D costs of 3D bioprinting create speculative pressure, turning the metric into a tool for monitoring capital dilution risks.

Key competitors

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|Crinetics Corp (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio newamsterdampharma.com (NAMS)|Forward Price-to-Revenue Multiple soleno.life SLNO|Forward P/S Multiple FOLD (amicusrx.com)|Market Cap to Expected Sales Ratio 89bio (ETNB)|Agios - Forward P/S Multiple|Structure Corp - Price to Expected Revenue Ratio|mimedx.com (MDXG) - Price-to-Projected Revenue Ratio|Future Price to Revenue RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio MBX|Price-to-Projected Revenue Ratio Altimmune Pharma (ALT)|Price-to-Projected Revenue Ratio AARD (Aardvark Therapeutics Corp)|Forward P/S Multiple SGMT (Sagimet Biosciences, Inc.)|BioAge (BIOA) - Market Cap to Future Revenue Ratio|BMEA: Forward Price-to-Revenue Multiple|Forward Price to Sales QNCX (Quince Therapeutics Inc)|GUTS (Fractyl) - Forward Price-to-Revenue Multiple|vTv Therapeutics, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Agape ATP Corp.|Forward Price-to-Revenue Multiple Pluri (PLUR)|Forward P/S Multiple SYBX|Market Cap to Expected Sales Ratio Lipocine Inc|Price-to-Projected Revenue Ratio Matinas BioPharma Holdings MTNB|Market Cap to Expected Sales Ratio Spruce Biosciences (SPRB)|GLTO: Forward Price-to-Revenue Multiple|Future Price to Revenue CTCX|LUMO (Lumos Pharma) - Forward Price-to-Revenue Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio